JP2019023243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019023243A5 JP2019023243A5 JP2018218127A JP2018218127A JP2019023243A5 JP 2019023243 A5 JP2019023243 A5 JP 2019023243A5 JP 2018218127 A JP2018218127 A JP 2018218127A JP 2018218127 A JP2018218127 A JP 2018218127A JP 2019023243 A5 JP2019023243 A5 JP 2019023243A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- phosphatidyl
- liposome
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553786P | 2011-10-31 | 2011-10-31 | |
| US61/553,786 | 2011-10-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017044663A Division JP6549172B2 (ja) | 2011-10-31 | 2017-03-09 | がん治療用組合せリポソーム組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019088222A Division JP2019123753A (ja) | 2011-10-31 | 2019-05-08 | がん治療用組合せリポソーム組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019023243A JP2019023243A (ja) | 2019-02-14 |
| JP2019023243A5 true JP2019023243A5 (cg-RX-API-DMAC7.html) | 2019-06-13 |
Family
ID=47146747
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539143A Expired - Fee Related JP6143767B2 (ja) | 2011-10-31 | 2012-10-31 | がん治療用組合せリポソーム組成物 |
| JP2017044663A Expired - Fee Related JP6549172B2 (ja) | 2011-10-31 | 2017-03-09 | がん治療用組合せリポソーム組成物 |
| JP2018218127A Pending JP2019023243A (ja) | 2011-10-31 | 2018-11-21 | がん治療用組合せリポソーム組成物 |
| JP2019088222A Pending JP2019123753A (ja) | 2011-10-31 | 2019-05-08 | がん治療用組合せリポソーム組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539143A Expired - Fee Related JP6143767B2 (ja) | 2011-10-31 | 2012-10-31 | がん治療用組合せリポソーム組成物 |
| JP2017044663A Expired - Fee Related JP6549172B2 (ja) | 2011-10-31 | 2017-03-09 | がん治療用組合せリポソーム組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019088222A Pending JP2019123753A (ja) | 2011-10-31 | 2019-05-08 | がん治療用組合せリポソーム組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9370489B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3424564A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6143767B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140097215A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104023793B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014010291A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2852564A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2694154T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL232344B (cg-RX-API-DMAC7.html) |
| MX (1) | MX360391B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2640934C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013066903A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2768444A1 (en) * | 2009-07-17 | 2011-01-20 | Rigshospitalet | Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| PL4332576T3 (pl) | 2013-03-15 | 2025-09-08 | Translate Bio, Inc. | Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane |
| JP2014227338A (ja) * | 2013-05-17 | 2014-12-08 | キヤノン株式会社 | インドシアニングリーン含有粒子およびその製造方法 |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| DK3138555T3 (da) | 2014-04-30 | 2020-12-14 | Fujifilm Corp | Liposomsammensætning og fremgangsmåde til fremstilling heraf |
| CN107921005A (zh) * | 2015-02-13 | 2018-04-17 | 友杏生技医药股份有限公司 | 利用纳米颗粒治疗肿瘤的组合物和方法 |
| WO2016141167A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| US10736845B2 (en) | 2015-03-03 | 2020-08-11 | Cureport Inc. | Dual loaded liposomal pharmaceutical formulations |
| WO2016146516A1 (en) * | 2015-03-17 | 2016-09-22 | Leon-Nanodrugs Gmbh | Nanoparticles comprising a stabilized boronic acid compound |
| EP3277264A4 (en) * | 2015-04-02 | 2018-07-18 | The Research Foundation for the State University of New York | Serum-stable compositions and methods for light-triggered release of materials |
| ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| WO2017078008A1 (ja) * | 2015-11-02 | 2017-05-11 | 富士フイルム株式会社 | ゲムシタビンリポソーム組成物を含む腫瘍治療剤およびキット |
| EP3377043A4 (en) * | 2015-11-20 | 2019-06-26 | The Regents of The University of California | DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN |
| WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| US20200282101A1 (en) * | 2015-12-18 | 2020-09-10 | Medigear International Corporation | Biodegradable tumor sealant |
| EP4036079B1 (en) | 2015-12-22 | 2025-11-19 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| KR101630397B1 (ko) * | 2015-12-31 | 2016-06-24 | 한국과학기술원 | 항암제-인도시아닌 그린-리포좀 복합체를 포함하는 암 치료용 조성물 |
| EP3416623B1 (en) | 2016-02-15 | 2021-08-11 | University of Georgia Research Foundation, Inc. | Ipa-3-loaded liposomes and methods of use thereof |
| US11266602B2 (en) | 2016-05-16 | 2022-03-08 | Infectious Disease Research Institute | PEGylated liposomes and methods of use |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CN106474057A (zh) * | 2016-12-02 | 2017-03-08 | 中国药科大学 | 一种奥沙利铂热敏长循环脂质体的蔗糖溶液制剂及其制备方法 |
| CN110381922A (zh) * | 2017-01-18 | 2019-10-25 | 淡马锡生命科学研究院有限公司 | 超稳定脂质体增加对有丝分裂细胞的靶向作用 |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
| WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| US10925831B2 (en) * | 2017-08-28 | 2021-02-23 | Wake Forest University | Liposomal formulations of platinum-acridine anticancer agents and methods thereof |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| US11110060B2 (en) * | 2017-10-25 | 2021-09-07 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
| US10606661B2 (en) * | 2017-12-15 | 2020-03-31 | Rubrik, Inc. | On-demand provisioning of customized developer environments |
| EP3811949B1 (en) | 2018-06-20 | 2024-07-03 | FUJIFILM Corporation | Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3852732A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Peg lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| WO2020115171A1 (en) * | 2018-12-06 | 2020-06-11 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| RU2706427C1 (ru) * | 2018-12-27 | 2019-11-19 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" | Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата |
| JP7253735B2 (ja) | 2019-07-02 | 2023-04-07 | パナソニックＩｐマネジメント株式会社 | 通過可否判定装置、通過管理システム、通過可否判定方法、及び、コンピュータプログラム |
| AR120080A1 (es) | 2019-09-19 | 2022-02-02 | Modernatx Inc | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos |
| EP4031142A1 (en) | 2019-09-19 | 2022-07-27 | Danmarks Tekniske Universitet | Immune stimulating micelle composition |
| US20220364139A1 (en) * | 2019-09-24 | 2022-11-17 | Pataigin, Llc | Methods for determining growth and response |
| CN110571005B (zh) * | 2019-09-27 | 2021-01-01 | 广西科技大学 | 一种固定化金属离子-磁性脂质体及其制备方法和应用 |
| EP4199906A1 (en) * | 2020-08-20 | 2023-06-28 | Bionanosim (BNS) Ltd | Lipid delivery systems for delivery of oxaliplatin palmitate acetate |
| KR102560135B1 (ko) | 2020-12-04 | 2023-07-27 | 가톨릭대학교 산학협력단 | 표적 치료제의 효과적인 전달을 위한 다기능성 리포좀 조성물 |
| US20240229154A9 (en) | 2021-02-12 | 2024-07-11 | Institut National de la Santé et de la Recherche Médicale | Method for prognosis and treating a patient suffering from cancer |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4306126A1 (en) | 2021-03-08 | 2024-01-17 | Eyegene Inc. | Vaccine composition for preventing sars-cov-2 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023087A (en) * | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
| WO1997038010A2 (en) | 1996-04-11 | 1997-10-16 | The University Of British Columbia | Fusogenic liposomes |
| US6897196B1 (en) | 2001-02-07 | 2005-05-24 | The Regents Of The University Of California | pH sensitive lipids based on ortho ester linkers, composition and method |
| US7273620B1 (en) * | 2002-05-20 | 2007-09-25 | University Of British Columbia | Triggered release of liposomal drugs following mixing of cationic and anionic liposomes |
| US7149468B2 (en) | 2002-07-25 | 2006-12-12 | The Mcgraw-Hill Companies, Inc. | Methods for improving certainty of test-taker performance determinations for assessments with open-ended items |
| AU2002350719A1 (en) * | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| WO2004103344A1 (en) | 2003-05-20 | 2004-12-02 | Aronex Pharmaceuticals, Inc. | Combination chemotherapy comprising a liposomal platinum complex |
| EP1695696A1 (en) * | 2003-12-01 | 2006-08-30 | Mitsubishi Pharma Corporation | Liposome |
| TWI262798B (en) * | 2003-12-31 | 2006-10-01 | Ind Tech Res Inst | Liposome and drug deliver system |
| US20110020434A1 (en) | 2005-09-02 | 2011-01-27 | O'halloran Thomas V | Nanoparticle arsenic-platinum compositions |
| WO2007049279A2 (en) * | 2005-10-26 | 2007-05-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A liposomal combination and uses thereof |
-
2012
- 2012-10-31 EP EP18189596.2A patent/EP3424564A1/en not_active Withdrawn
- 2012-10-31 WO PCT/US2012/062635 patent/WO2013066903A1/en not_active Ceased
- 2012-10-31 EP EP12783805.0A patent/EP2773426B1/en not_active Not-in-force
- 2012-10-31 CN CN201280064482.6A patent/CN104023793B/zh not_active Expired - Fee Related
- 2012-10-31 MX MX2014004960A patent/MX360391B/es active IP Right Grant
- 2012-10-31 BR BR112014010291A patent/BR112014010291A2/pt not_active Application Discontinuation
- 2012-10-31 CA CA2852564A patent/CA2852564A1/en not_active Abandoned
- 2012-10-31 RU RU2014120216A patent/RU2640934C2/ru not_active IP Right Cessation
- 2012-10-31 ES ES12783805.0T patent/ES2694154T3/es active Active
- 2012-10-31 US US13/664,457 patent/US9370489B2/en not_active Expired - Fee Related
- 2012-10-31 JP JP2014539143A patent/JP6143767B2/ja not_active Expired - Fee Related
- 2012-10-31 KR KR1020147014027A patent/KR20140097215A/ko not_active Ceased
-
2014
- 2014-04-29 IL IL232344A patent/IL232344B/en active IP Right Grant
-
2016
- 2016-05-23 US US15/162,072 patent/US9717686B2/en not_active Expired - Fee Related
-
2017
- 2017-03-09 JP JP2017044663A patent/JP6549172B2/ja not_active Expired - Fee Related
- 2017-07-28 US US15/663,472 patent/US10213385B2/en not_active Expired - Fee Related
-
2018
- 2018-04-16 IL IL258740A patent/IL258740B/en unknown
- 2018-11-21 JP JP2018218127A patent/JP2019023243A/ja active Pending
-
2019
- 2019-02-19 US US16/279,977 patent/US20190175505A1/en not_active Abandoned
- 2019-05-08 JP JP2019088222A patent/JP2019123753A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019023243A5 (cg-RX-API-DMAC7.html) | ||
| JP2014532665A5 (cg-RX-API-DMAC7.html) | ||
| RU2014120216A (ru) | Комбинационные липосомальные композиции для лечения рака | |
| WO2010041255A2 (en) | Liposomal systems comprising sphingomyelin | |
| JP2019006815A5 (cg-RX-API-DMAC7.html) | ||
| CN101043875B (zh) | 糖皮质激素和糖皮质激素衍生物的脂质体组合物 | |
| Nekkanti et al. | Recent advances in liposomal drug delivery: a review | |
| JP2015515992A5 (cg-RX-API-DMAC7.html) | ||
| IL278079B1 (en) | Inhalable liposomal sustained release compound for use in the treatment of pulmonary diseases | |
| JP2018184470A5 (cg-RX-API-DMAC7.html) | ||
| JP2006509750A (ja) | リポソームグルココルチコイド | |
| JP3202999B2 (ja) | 肝移行性リポソーム製剤 | |
| JP2015502400A5 (cg-RX-API-DMAC7.html) | ||
| JP2015519383A5 (cg-RX-API-DMAC7.html) | ||
| US20170281541A1 (en) | Liposome-based mucus-penetrating particles for mucosal delivery | |
| EP2498792B1 (en) | Compositions comprising phospholipid carriers for the treatment of otitis externa | |
| JPWO2019209787A5 (cg-RX-API-DMAC7.html) | ||
| JP2018527335A5 (cg-RX-API-DMAC7.html) | ||
| TWI767133B (zh) | 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途 | |
| JP2007529546A (ja) | 吸入によるシスプラチンの投与 | |
| JP2003522193A (ja) | ホスホリパーゼａ２で分解可能な脂質誘導体を含有する脂質をベースとした薬物送達系、および治療におけるその使用 | |
| EP1610763A2 (en) | Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer | |
| Matole et al. | Need of liposomes as a novel drug delivery system | |
| US7008791B1 (en) | Liposome-entrapped DNA oral vaccines | |
| EP2231190A1 (en) | Particulate drug carriers as desensitizing agents |